The "triple-witching hour" is the one before the market closes on that day (from 2 to 3 p.m. Central time), and it's when the stock market is likely to be more volatile than usual as traders buy and sell various securities before the final bell. Most options and futures represent contracts based on short-term pricing rather than long-term growth. If you're interested in a company developing cutting-edge treatments for cancer and inflammatory diseases, consider fast-growing Celgene (Nasdaq: CELG), with a market value recently topping $100 billion. Celgene sports the blockbuster cancer drug Revlimid, and its ability to continually expand Revlimid's label for new indications, such as newly diagnosed multiple myeloma, has boosted its earnings and revenue. The net result of "growth by label expansion" has been soaring sales volumes. Better still, Celgene has a deep pipeline of drugs in development and isn't threatened by looming patent expirations, as most of its best-selling drugs appear to be protected well into the 2020s.